Posts Tagged ‘anti-C5’

February 23, 2012

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h02/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h02/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h02/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Antibody-mediated rejection (ABMR)in the presence of high levels of donor-specific antibodies (DSA) likely involves complement activation as part of the mechanism of graft damage. This study examined the efficacy of inhibiting complement activation by neutralizing C5 with a humanized anti-C5 antibody; eculizumab. The effect of anti-C5 treatment was assessed in 26 highly sensitized recipients of […]

No Comments Posted in Renal Transplantation